Search the Newsreel

Jazz Pharmaceuticals Bolsters Epilepsy Division With Actio Biosciences Buyout (JAZZ)

Wedge Capital Management L L P NC Sells 33,467 Shares of Jazz Pharmaceuticals PLC $JAZZ

Wedge Capital Management L L P NC reduced its stake in Jazz Pharmaceuticals PLC by 20.9% in the second quarter, selling 33,467 shares and retaining 126,539 shares valued at approximately $30.5 million. Despite missing quarterly EPS estimates, the company's revenue exceeded expectations, and analysts …

Jazz Pharmaceuticals (JAZZ) Q2 2026 Earnings Call Transcript

Royal Bank of Canada Has $8.56 Million Stake in Jazz Pharmaceuticals PLC $JAZZ

Royal Bank of Canada increased its stake in Jazz Pharmaceuticals PLC by 17.4% in the first quarter, now holding 45,251 shares valued at $8.56 million. Institutional investors collectively own 89.14% of JAZZ shares, reflecting positive sentiment despite a recent EPS miss. Jazz Pharmaceuticals reported …

Jazz to buy rare epilepsy drugmaker in potentially $1.3B deal

Jazz Pharmaceuticals has agreed to acquire Actio Biosciences, a private biotech specializing in genetic epilepsy treatments, for an upfront payment of $820 million and potential milestone payments of $500 million, totaling $1.3 billion. The acquisition will bolster Jazz's neuroscience pipeline, particularly with Actio's lead …

Jazz Pharmaceuticals to Acquire Rare Epilepsy Specialist Actio

Jazz Pharmaceuticals (JAZZ) announced its acquisition of Actio Biosciences for $820 million upfront and up to $500 million in milestone payments, expected to close by late 2026. This strategic move strengthens Jazz's rare epilepsy portfolio with the addition of ABS-1230, a promising therapy for …

Jazz Pharmaceuticals to acquire Actio Biosciences for $820M

Jazz Pharmaceuticals announced its acquisition of Actio Biosciences for an upfront payment of $820 million, with potential additional payments of up to $500 million tied to milestones. The acquisition is primarily focused on ABS-1230, a clinical-stage drug for KCNT1+ epilepsy, a rare genetic disorder …

5 Revealing Analyst Questions From Jazz Pharmaceuticals’s Q2 Earnings Call

5 Revealing Analyst Questions From Jazz Pharmaceuticals's Q2 Earnings Call Jazz Pharmaceuticals delivered a positive Q2, with a strong 16% year-over-year revenue increase driven primarily by its oncology and rare disease portfolios. Management attributed the quarter's performance to robust demand for flagship products like …

Jazz Pharmaceuticals plc (JAZZ) stock price, news, quote and history

This article provides a detailed overview of Jazz Pharmaceuticals plc (JAZZ), including its stock price, news, and historical data. It covers the company's financial performance, product pipeline, analyst ratings, and compares it with similar biotechnology companies. The information presented aims to give investors a …

Jazz Pharmaceuticals PLC (JAZZ) Earnings Forecast: Future EPS & Revenue Growth Estimates

This article provides an earnings forecast for Jazz Pharmaceuticals PLC (JAZZ), highlighting its current earnings forecast score, average price target, and analyst ratings. It details expected future EPS and revenue growth, along with recent performance and a peer comparison. The forecast indicates a "Buy" …

Jazz Pharmaceuticals plc 2026 Q2 - Results - Earnings Call Presentation (NASDAQ:JAZZ) 2026-08-07

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) published its Q2 2026 earnings call presentation, detailing its financial results. The company reported an EPS of $5.71, missing estimates by $0.47, but revenue reached $1.21 billion, surpassing expectations by $93.90 million with a 15.55% year-over-year increase. This presentation provides …

Jazz Pharmaceuticals plc SEC Filing (Aug 7, 2026)

Jazz Pharmaceuticals plc has filed a Form 144 SEC filing on August 7, 2026, concerning a proposed sale of securities. The filing indicates a neutral impact and sentiment according to AI-generated analysis by StockTitan. It details information about the issuer, the filer (Etrade Financial …

Jazz Pharmaceuticals plc (JAZZ) News, Articles, Events & Latest Updates

Jazz Pharmaceuticals (JAZZ) reported strong Q2 2026 results, exceeding sales estimates and raising its 2026 revenue guidance, despite an EPS miss. The company's performance was driven by robust demand in its oncology and neuroscience segments, leading to a stock jump and mixed analyst reactions, …

Jazz Pharmaceuticals Plc Just Missed EPS By 13%: Here's What Analysts Think Will Happen Next

Jazz Pharmaceuticals Plc recently reported its quarterly earnings, missing analyst EPS estimates by 13%. This article discusses the company's latest financial results and provides an overview of how analysts are adjusting their future earnings and revenue forecasts in light of this performance. It highlights …

FMR LLC and Abigail Johnson disclose 7.4% Jazz Pharmaceuticals (JAZZ) ownership

FMR LLC and Abigail P. Johnson have reported beneficial ownership of 7.4% of Jazz Pharmaceuticals plc common stock, according to a SCHEDULE 13G SEC filing. FMR LLC holds 4,675,458.82 shares, with sole voting power over 4,618,210.03 shares and sole dispositive power over all its …

Jazz Pharmaceuticals (JAZZ) Director Bruce Cozadd Sells 6,000 Sh

Jazz Pharmaceuticals Director Bruce Cozadd sold 6,000 shares of JAZZ for approximately $1.52 million, bringing his total sales over the past year to 143,000 shares with no purchases. This insider selling activity, combined with the stock trading significantly above its GF Value (price-to-GF-Value ratio …

Jazz Pharmaceuticals (JAZZ) Stock May Stay Below Fair Value Following Raised Guidance

Jazz Pharmaceuticals' stock has seen a significant surge over the past year, returning 146.9%. Despite this, the company's valuation metrics, particularly its P/E ratio of 18.0x, suggest it might still be undervalued compared to a tailored reference multiple of 24.7x, even after record Q2 …

Jazz Pharmaceuticals plc Stock 12‑Month Price Target Raised to $285, Implies 13% Upside

Jazz Pharmaceuticals plc's average 12-month price target has been increased from $270.63 to $285 by 19 analysts, suggesting a 13% potential upside from its August 3rd closing price. The consensus rating for JAZZ stock remains a "Buy" among 22 analysts, with 19 recommending Buy, …

Jazz Pharmaceuticals (JAZZ) Stock Climbs As Raised Guidance Backs Oncology Push

Jazz Pharmaceuticals (JAZZ) saw its stock climb after reporting record Q2 revenue and raised full-year guidance, driven by strong performance in its neurology segment and progress in oncology. The company's Q2 revenue hit US$1.21 billion with non-GAAP EPS of US$5.71, leading to an increased …

Jazz Pharmaceuticals stock hits all-time high at 261.46 USD By Investing.com

Jazz Pharmaceuticals (JAZZ) stock has reached an all-time high of $261.46, marking a 130.32% increase over the past year. Despite trading near its 52-week high, InvestingPro analysis suggests the stock is undervalued. The company also reported strong second-quarter revenues of $1.21 billion, exceeding estimates, …

California State Teachers Retirement System Grows Position in Jazz Pharmaceuticals PLC $JAZZ

The California State Teachers Retirement System increased its stake in Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) by 22% in the first quarter of 2026, now holding 63,657 shares valued at $12 million. Other institutional investors also significantly grew their positions. Analysts maintain a generally bullish outlook …

Jazz Pharmaceuticals (NASDAQ:JAZZ) Reports Bullish Q2 CY2026, Guides for Strong Full-Year Sales

RBC Capital Adjusts Price Target on Jazz Pharmaceuticals to $273 From $258, Maintains Outperform Rating

RBC Capital has raised its price target for Jazz Pharmaceuticals (JAZZ) from $258 to $273, while reiterating an Outperform rating on the stock. This adjustment comes amidst other analyst updates for the biopharmaceutical company, including price target increases from Deutsche Bank and Morgan Stanley. …

What Jazz Pharmaceuticals’ Q2 Earnings Call Revealed About the Zanidatamab Bet

Jazz Pharmaceuticals reported a record Q2 revenue of $1.21 billion, a 16% year-over-year increase, prompting the company to raise its full-year revenue guidance. The strong performance was driven by significant growth in oncology sales and better-than-expected Xywav sales despite generic competition, attributed to strong …

Stifel raises Jazz Pharmaceuticals stock price target on revenue beat

JAZZ Q2 Earnings Miss, Sales Beat, Stock Jumps on Raised '26 View

Jazz Pharmaceuticals (NASDAQ:JAZZ) Issues Earnings Results, Misses Expectations By $0.47 EPS

Jazz Pharmaceuticals plc Q2 2026: Revenue $1156.1M, EPS $2.78— 10-Q Summary

Jazz Pharmaceuticals plc reported strong Q2 2026 results with revenue of $1156.1M and diluted EPS of $2.78, marking a significant improvement from the prior year's loss. Growth was fueled by key product performance, including Xywav and Epidiolex, and successful oncology launches. The company also …

Jazz Pharmaceuticals (JAZZ) swings to H1 2026 profit and trims $1B in debt

Jazz Pharmaceuticals reported a significant financial turnaround in the first half of 2026, swinging to a net income of $485.9 million compared to a net loss of $811.0 million in the prior-year period. Revenues also increased to $2,277.2 million. The company successfully reduced its …

Jazz Pharmaceuticals plc (JAZZ) Earnings Preview

This article previews Jazz Pharmaceuticals plc's upcoming earnings report, highlighting the company's position as a global biopharmaceutical player in neuroscience and oncology. It emphasizes key challenges and opportunities, including the transition of its oxybate franchise, pipeline execution, and the need to sustain profitability amidst …

Compared to Estimates, Jazz (JAZZ) Q2 Earnings: A Look at Key Metrics

Jazz Pharmaceuticals (JAZZ) Earnings Date and Reports 2026 $JAZZ

Jazz Pharmaceuticals (JAZZ) Q2 Earnings Lag Estimates